Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Yale University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07398404CT.gov A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients | — | Not Yet Recruiting | — | — | — |
NCT07224087CT.gov Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients | — | Recruiting | — | — | — |
NCT07213466CT.gov Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder | — | Recruiting | — | — | — |
NCT06620562CT.gov Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet | — | Recruiting | — | — | — |
NCT06854614CT.gov Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) | — | Active Not Recruiting | — | — | — |
NCT06605703CT.gov A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial) | — | Completed | — | — | — |
NCT06098079CT.gov Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) | — | Active Not Recruiting | — | — | — |
NCT05919797CT.gov Weight Loss Study: Genetics and Response to Naltrexone/Bupropion | — | Recruiting | — | — | — |
NCT05756764CT.gov Anti-obesity Pharmacotherapy and Inflammation | — | Active Not Recruiting | — | — | — |
NCT05157698CT.gov Pharmacological and Behavioral Treatment After Bariatric Surgery | — | Active Not Recruiting | — | — | — |
Show 30 more trialsShow fewer
NCT04605081CT.gov Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) | — | Active Not Recruiting | — | — | — |
NCT04662801CT.gov Weight Regain Treatment Post-Bariatric Surgery | — | Completed | — | — | — |
NCT04599478CT.gov Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) | — | Active Not Recruiting | — | — | — |
NCT04587843CT.gov A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery | — | Unknown | — | — | — |
NCT04589130CT.gov Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program. | — | Unknown | — | — | — |
NCT04399395CT.gov Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery | — | Withdrawn | — | — | — |
NCT04575194CT.gov Study of the Cardiometabolic Effects of Obesity Pharmacotherapy | — | Unknown | — | — | — |
NCT04531176CT.gov EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial | — | Terminated | — | — | — |
NCT03946111CT.gov Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders | — | Completed | — | — | — |
NCT03799198CT.gov Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity | — | Completed | — | — | — |
NCT03374956CT.gov Individualized Obesity Pharmacotherapy | — | Completed | — | — | — |
NCT03063606CT.gov Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment | — | Completed | — | — | — |
NCT03047005CT.gov Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy | — | Completed | — | — | — |
NCT03581630CT.gov Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients | — | Completed | — | — | — |
NCT03132571CT.gov Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia | — | Terminated | — | — | — |
NCT03045341CT.gov Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment | — | Completed | — | — | — |
NCT02736474CT.gov Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia | — | Completed | — | — | — |
NCT02638129CT.gov Naltrexone/Bupropion Cardiovascular Outcomes Study | — | Terminated | — | — | — |
NCT01764386CT.gov Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects | — | Completed | — | — | — |
NCT01601704CT.gov Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) | — | Terminated | — | — | — |
NCT01623440CT.gov Food Reward in Native American Women | — | Completed | — | — | — |
NCT00976066CT.gov [11C]Carfentanil PET Study of GSK1521498 | — | Completed | — | — | — |
NCT00793780CT.gov Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia | — | Completed | — | — | — |
NCT00711477CT.gov A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects | — | Completed | — | — | — |
NCT00567255CT.gov A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects | — | Completed | — | — | — |
NCT00532779CT.gov A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects | — | Completed | — | — | — |
NCT00563563CT.gov A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent | — | Completed | — | — | — |
NCT00474630CT.gov A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes | — | Completed | — | — | — |
NCT00456521CT.gov A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program | — | Completed | — | — | — |
NCT00364871CT.gov Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Naltrexone (this asset) | Yale University | Approved | BB · 69 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Naltrexone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alcohol Dependence | — | P4 | BBB · 79 |
| Osteoarthritis | — | P4 | BBB · 75 |
| Rheumatoid Arthritis | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Naltrexone in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/naltrexone-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →